1
|
Smolarska A, Pruszynska I, Wasylko W, Godlewska K, Markowska M, Rybak A, Botther J, Kucharzewska P, Nowakowska J, Szeliga J, Kubiak M, Gorczak M, Krol M. Targeted therapies for glioblastoma treatment. J Physiol Pharmacol 2023; 74. [PMID: 37661178 DOI: 10.26402/jpp.2023.3.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 01/21/2023] [Accepted: 06/30/2023] [Indexed: 09/05/2023]
Abstract
Glioblastoma, the most common and aggressive type of brain tumor in adults, poses significant challenges in terms of treatment. Conventional approaches including surgery, chemotherapy, and radiotherapy have yielded limited success, with a median survival of approximately 15 months. However, extensive research into the biology of glioblastoma has identified molecular targets that can be exploited by newly developed drugs, leading to the emergence of precise personalized therapies. Several innovative treatment strategies are currently under development, aiming to enhance effectiveness while minimizing side effects. Clinical trials are underway to evaluate the efficacy of monoclonal antibodies that target glioblastoma cells, either by blocking specific receptors or by modifying molecular interactions that impede cell proliferation. Another promising avenue involves the use of oncolytic viruses designed to selectively infect glioblastoma cells. Additionally, the review explores the utilization of nanocarriers capable of surmounting the formidable obstacle of the blood-brain barrier, enabling efficient drug delivery. Cell therapies represent another promising approach, with dendritic cells, chimeric antigen receptor-T cells, and macrophages emerging as potential treatment modalities. By summarizing recent advances in targeted therapies against glioblastoma, this review aims to provide a comprehensive overview of ongoing efforts to discover effective and safe methods for treating glioblastoma patients. The ultimate goal is to improve patient outcomes and transform the landscape of glioblastoma treatment.
Collapse
Affiliation(s)
- A Smolarska
- Department of Cancer Biology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland
| | - I Pruszynska
- Department of Cancer Biology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland
| | - W Wasylko
- Department of Cancer Biology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland
| | - K Godlewska
- Department of Cancer Biology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland
| | - M Markowska
- Department of Cancer Biology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland
| | - A Rybak
- Department of Cancer Biology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland
| | - J Botther
- Department of Cancer Biology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland
| | - P Kucharzewska
- Department of Cancer Biology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland
| | - J Nowakowska
- Department of Cancer Biology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland
| | - J Szeliga
- Department of Cancer Biology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland
| | - M Kubiak
- Department of Cancer Biology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland
| | - M Gorczak
- Department of Cancer Biology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland
| | - M Krol
- Department of Cancer Biology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland.
| |
Collapse
|
2
|
Taciak B, Pruszynska I, Kiraga L, Bialasek M, Krol M. Wnt signaling pathway in development and cancer. J Physiol Pharmacol 2018; 69. [PMID: 29980141 DOI: 10.26402/jpp.2018.2.07] [Citation(s) in RCA: 86] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 02/14/2018] [Accepted: 04/26/2018] [Indexed: 01/18/2023]
Abstract
Wnt signaling pathway is one of the most important signaling pathways. The complexity of Wnt signals and their functional role is crucial in development and growth. It is the most active during embryogenesis facilitating new organism formation by cell differentiation, polarization and migration. Its activation is also common during development of many tumors and others diseases. In this review we shortly describe a role of Wnt pathway in development in order to better understand its role in cancer progression. We also describe current anti-cancer therapies targeting Wnt pathway.
Collapse
Affiliation(s)
- B Taciak
- Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences - SGGW, Warsaw, Poland
| | - I Pruszynska
- Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences - SGGW, Warsaw, Poland
| | - L Kiraga
- Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences - SGGW, Warsaw, Poland
| | - M Bialasek
- Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences - SGGW, Warsaw, Poland
| | - M Krol
- Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences - SGGW, Warsaw, Poland.
| |
Collapse
|